Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743662 · ClinicalTrials.gov registry record · Phase 2
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT03743662 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT03743662, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- PROCEDURE Re-resection
- RADIATION Re-irradiation (RT)
Study Locations (11)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Connecticut
- Hartford Healthcare (Data Collection) - Hartford
Indiana
- Indiana University (Data Collection Only) - Indianapolis
Pennsylvania
- Lehigh Valley Health Network (Data Collection Only) - Allentown
Vermont
- University of Vermont Medical Center (Data Collection Only) - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03743662
The ClinicalTrials.gov registry entry for NCT03743662 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03743662 reports 11 study locations spanning 6 distinct geographic areas - top geographies include New York, New Jersey, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03743662 about?
NCT03743662 is a clinical study titled "Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma". This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
What is the current status of trial NCT03743662?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2018-11-12. Estimated completion is 2026-11.
What conditions does trial NCT03743662 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03743662?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), Re-resection (PROCEDURE), Re-irradiation (RT) (RADIATION).
Who is sponsoring clinical trial NCT03743662?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03743662 being conducted?
This trial has 11 study locations across Connecticut, Indiana, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.